BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$0.62 USD
-0.02 (-3.18%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $0.62 +0.01 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
BioXcel Therapeutics, Inc. (BTAI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.60 | $7.00 | $1.00 | 618.75% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for BioXcel Therapeutics, Inc. comes to $4.60. The forecasts range from a low of $1.00 to a high of $7.00. The average price target represents an increase of 618.75% from the last closing price of $0.64.
Analyst Price Targets (5 )
Broker Rating
BioXcel Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, three are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BTAI.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/9/2024 | UBS | Colin N Bristow | Hold | Hold |
8/7/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
7/15/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Hold | Hold |
6/27/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
1/3/2024 | Guggenheim Securities | Yatin Suneja | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 6 |
Average Target Price | $4.60 |
LT Growth Rate | 41.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.45 |